Transfusion Therapy for Coagulation Factor Deficiencies

Chapter 52 Transfusion Therapy for Coagulation Factor Deficiencies



Elizabeth Roman, Peter J. Larson, Catherine S. Manno




Table 52-1 Dosing Regimens for Bleeding and Prophylaxis in Hemophilia

image

qod, Every other day.


* Depending on severity.


† Painless spontaneous hematuria often requires no treatment other than fluid intake. Persistence requires treatment and evaluation.


‡ Use of a schedule of 25 U/kg qod and a dose of 40 U/kg with an interval of 2 days between the next dose may increase compliance by decreasing infusions to three per week.


Data from DiMichele D: Hemophilia 1996. New approach to an old disease. Pediatr Clin North Am 43:709, 1996; Mannucci PM: Haemophilia treatment protocols around the world: Towards a consensus. Haemophilia 4:421, 1998; and Lusher J: Treatment of congenital coagulopathies, 1999, AABB Press.



1-Deamino 8-D Arginine Vasopressin Trial




1. Collect citrated plasma from the patient immediately before DDAVP infusion for testing with the postinfusion blood specimen.


2. Administer DDAVP intravenously (0.3 µg/1 kg) in 25 to 50 mL normal saline.

Related posts:

Heme Biosynthesis and Its Disorders: Sideroblastic Anemia Infectious Mononucleosis and Other Epstein-Barr Virus–Associated Diseases: Part 2 Thrombotic Thrombocytopenic Purpura and the Hemolytic Uremic Syndrome Hematology in Aging Disorders of Phagocyte Function Inherited Forms of Bone Marrow Failure
Tags:
Jun 12, 2016 | Posted by in HEMATOLOGY | Comments Off on Transfusion Therapy for Coagulation Factor Deficiencies
Premium Wordpress Themes by UFO Themes